FDA is proposing to add to certain
labeling requirements concerning aluminum in LVP's and SVP's used
in TPN. FDA is also proposing to specify an upper limit of aluminum
permitted in LVP's and to require applicants and manufacturers to
develop and to submit to FDA for approval validated assay methods
for determining aluminum content in parenteral drug products
containing aluminum to morbidity and mortality among patients in
TPN therapy, especially among premature neonates and patients with
impaired kidney function.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.